ACVR1 and fibrodysplasia ossificans progressiva: Here, we address whether an antibody directed against the extracellular domain (ECD) of ACVR1(R206H) that interferes with ligand-dependent receptor activation would inhibit HO and constitute a potential therapeutic approach for FOP.